Company Profile

Company Honor

Leadership Team

Cooperation Unit

Picture Name

2015

Veronte was established
Picture Name

2017

Initiate the industrialization of oncolytic virus M1 first VRT106 product
Picture Name

2018

Undertake the national 13th Five-Year major new drug creation project (the first genetic engineering product project)
Picture Name

2022

VRT106 for indications "liver cancer" and "malignant glioma" were approved by the US FDA orphan drug qualification
Picture Name

2022

Oncolytic virus M1 core patent won the silver prize of the 23rd China Patent Award
Picture Name

2023

VRT106 received National Drug Administration (NMPA) clinical trial implied approval
Picture Name

2023

VRT106 Receives Implied Approval for Clinical Trials by Japan's Drug and Medical Device Agency (PMDA)

COMPANY HISTORY

Development process

2015

dd
Veronte was established

2017

dd
Initiate the industrialization of oncolytic virus M1 first VRT106 product

2018

dd
Undertake the national 13th Five-Year major new drug creation project (the first genetic engineering product project)

2022

dd
VRT106 for indications "liver cancer" and "malignant glioma" were approved by the US FDA orphan drug qualification

2022

dd
Oncolytic virus M1 core patent won the silver prize of the 23rd China Patent Award

2023

dd
VRT106 received National Drug Administration (NMPA) clinical trial implied approval
Veronide
Picture Name

Focus on us

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Contact Information

020-32030745

Monday to Friday 9:00~17:00

Virotech@virot.cn

Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City

Copyright©2024 Virotech Pharmaceutical Technology Co., Ltd.

粤ICP备XXXXXXXX号

Tags | city substation  | Business License | Powered by www.300.cn